Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti obesity treatments. The company is dealing with lower COVID related revenues and the halt of a key COVID vaccine trial while advancing mRNA and Lyme vaccine programs. Pfizer reports a pipeline of more than 100 candidates, alongside cost cutting efforts and balance sheet adjustments during this transition phase. For investors watching large pharma, Pfizer now sits at the intersection of established drug franchises and newer therapeutic areas. The Seagen and Metsera deals push the company further into oncology and metabolic disease, while its COVID franchise faces weaker demand and a stopped trial that could affect expectations around that segment. At the same time, Lyme vaccine progress and work in rare disease and mRNA reflect a broader shift in where research dollars are going. Looking ahead, the key questions for NYSE:PFE holders center on how quickly
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer (PFE) is now covered by CICC Research. They set an "outperform" rating on the stock.MarketBeat
- UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a "neutral" rating on the stock.MarketBeat
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/16/26 - Form 4
- 4/10/26 - Form 3
- 4/1/26 - Form 4
- PFE's page on the SEC website